Premium
Active and passive immunisation against respiratory syncytial virus
Author(s) -
Zambon Maria
Publication year - 1999
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/(sici)1099-1654(199910/12)9:4<227::aid-rmv251>3.0.co;2-k
Subject(s) - medicine , immunology , immune system , antibody , virus , palivizumab , bronchopulmonary dysplasia , immunization , disease , virology , pregnancy , biology , gestational age , genetics
RSV is a major cause of respiratory illness in infants under 2 years of age. Evidence is accumulating that it is also underestimated as a cause of respiratory infection in adults, the elderly and immunocompromised individuals. Active interventions to control the impact of RSV infection have been hampered by a lack of understanding of the immune response to RSV in different age groups. A number of different strategies for developing RSV vaccines have been pursued, including live attenuated vaccines, genetically engineered live and subunit vaccines and peptide vaccines with varying degrees of success. The target populations for RSV vaccines include infants, the elderly and women of childbearing age, but the efficacy of different vaccines may differ according to age. Desirable immune responses and immune correlates of protection to RSV in humans remain uncertain and determining these is critical for introduction of any vaccines. Prophylaxis and treatment of RSV in infants using human immunoglobulin containing high titres of RSV specific neutralising antibody (RSV‐Ig) has shown limited success in different infant populations. Prophylaxis of premature infants with RSV‐Ig, particularly those with bronchopulmonary dysplasia, has demonstrated limited clinical efficacy against RSV. In contrast, there are significant safety concerns for use of this preparation for prophylaxis in infants with congenital heart disease and no demonstrable efficacy in treatment of RSV disease in healthy infants. The cost of the preparation will limit use to highly selected infant groups. Production of humanised monoclonal antibodies to RSV offers another potential passive immunotherapy intervention for RSV, with increased specific activity and reduced side effects, although its use remains experimental. Copyright © 1999 John Wiley & Sons, Ltd.